APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Receptor Superfamily

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Receptor Superfamily Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025193 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Receptor Superfamily Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Receptor Superfamily Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Receptor Superfamily Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Receptor Superfamily Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Receptor Superfamily Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Receptor Superfamily market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Receptor Superfamily is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Receptor Superfamily is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Receptor Superfamily is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Receptor Superfamily include Ablynx NV, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, OncoMed Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc and Amgen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tumor Necrosis Factor Receptor Superfamily market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Receptor Superfamily and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Receptor Superfamily sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Receptor Superfamily market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Receptor Superfamily Segment by Company

Ablynx NV

Apogenix GmbH

Bristol-Myers Squibb Company

Five Prime Therapeutics Inc

Incyte Corp

MedImmune LLC

OncoMed Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Amgen Inc

Merck & Co Inc

Novartis AG

Tumor Necrosis Factor Receptor Superfamily Segment by Type

INCAGN-1876

GWN-323

FPA-154

BMS-986156

AMG-228

Others

Tumor Necrosis Factor Receptor Superfamily Segment by Application

Blood Cancer

Gastric Cancer

Melanoma

Non-Small Cell Lung Cancer

Others

Tumor Necrosis Factor Receptor Superfamily Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tumor Necrosis Factor Receptor Superfamily market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tumor Necrosis Factor Receptor Superfamily in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tumor Necrosis Factor Receptor Superfamily in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Receptor Superfamily Industry Trends Table 2. Tumor Necrosis Factor Receptor Superfamily Industry Drivers Table 3. Tumor Necrosis Factor Receptor Superfamily Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Receptor Superfamily Industry Restraints Table 5. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Receptor Superfamily Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Manufacturers Table 9. Global Tumor Necrosis Factor Receptor Superfamily Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Tumor Necrosis Factor Receptor Superfamily Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tumor Necrosis Factor Receptor Superfamily Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tumor Necrosis Factor Receptor Superfamily Manufacturers, Product Type & Application Table 13. Global Tumor Necrosis Factor Receptor Superfamily Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tumor Necrosis Factor Receptor Superfamily by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of INCAGN-1876 Table 17. Major Manufacturers of GWN-323 Table 18. Major Manufacturers of FPA-154 Table 19. Major Manufacturers of BMS-986156 Table 20. Major Manufacturers of AMG-228 Table 21. Major Manufacturers of Others Table 22. Global Tumor Necrosis Factor Receptor Superfamily Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021-2026) & (W Units) Table 24. Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2027-2032) & (W Units) Table 25. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Type (2021-2026) Table 26. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Type (2027-2032) Table 27. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2021-2026) & (W Units) Table 29. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2027-2032) & (W Units) Table 30. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Type (2021-2026) Table 31. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Blood Cancer Table 33. Major Manufacturers of Gastric Cancer Table 34. Major Manufacturers of Melanoma Table 35. Major Manufacturers of Non-Small Cell Lung Cancer Table 36. Major Manufacturers of Others Table 37. Global Tumor Necrosis Factor Receptor Superfamily Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021-2026) & (W Units) Table 39. Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2027-2032) & (W Units) Table 40. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Application (2021-2026) Table 41. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Application (2027-2032) Table 42. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 43. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2021-2026) & (W Units) Table 44. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2027-2032) & (W Units) Table 45. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Application (2021-2026) Table 46. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Application (2027-2032) Table 47. Global Tumor Necrosis Factor Receptor Superfamily Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Tumor Necrosis Factor Receptor Superfamily Sales by Region (2021-2026) & (W Units) Table 49. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Region (2021-2026) Table 50. Global Tumor Necrosis Factor Receptor Superfamily Sales Forecasted by Region (2027-2032) & (W Units) Table 51. Global Tumor Necrosis Factor Receptor Superfamily Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. North America Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2026) & (W Units) Table 54. North America Tumor Necrosis Factor Receptor Superfamily Sales by Country (2027-2032) & (W Units) Table 55. Europe Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Europe Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2026) & (W Units) Table 57. Europe Tumor Necrosis Factor Receptor Superfamily Sales by Country (2027-2032) & (W Units) Table 58. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2026) & (W Units) Table 60. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales by Country (2027-2032) & (W Units) Table 61. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2026) & (W Units) Table 63. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales by Country (2027-2032) & (W Units) Table 64. Global Tumor Necrosis Factor Receptor Superfamily Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Region (2021-2026) Table 68. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Region (2027-2032) Table 69. Ablynx NV Company Information Table 70. Ablynx NV Business Overview Table 71. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 73. Ablynx NV Recent Development Table 74. Apogenix GmbH Company Information Table 75. Apogenix GmbH Business Overview Table 76. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 78. Apogenix GmbH Recent Development Table 79. Bristol-Myers Squibb Company Company Information Table 80. Bristol-Myers Squibb Company Business Overview Table 81. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 83. Bristol-Myers Squibb Company Recent Development Table 84. Five Prime Therapeutics Inc Company Information Table 85. Five Prime Therapeutics Inc Business Overview Table 86. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 88. Five Prime Therapeutics Inc Recent Development Table 89. Incyte Corp Company Information Table 90. Incyte Corp Business Overview Table 91. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 93. Incyte Corp Recent Development Table 94. MedImmune LLC Company Information Table 95. MedImmune LLC Business Overview Table 96. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 98. MedImmune LLC Recent Development Table 99. OncoMed Pharmaceuticals Inc Company Information Table 100. OncoMed Pharmaceuticals Inc Business Overview Table 101. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 103. OncoMed Pharmaceuticals Inc Recent Development Table 104. Regeneron Pharmaceuticals Inc Company Information Table 105. Regeneron Pharmaceuticals Inc Business Overview Table 106. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 108. Regeneron Pharmaceuticals Inc Recent Development Table 109. Amgen Inc Company Information Table 110. Amgen Inc Business Overview Table 111. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 113. Amgen Inc Recent Development Table 114. Merck & Co Inc Company Information Table 115. Merck & Co Inc Business Overview Table 116. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 118. Merck & Co Inc Recent Development Table 119. Novartis AG Company Information Table 120. Novartis AG Business Overview Table 121. Novartis AG Tumor Necrosis Factor Receptor Superfamily Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Novartis AG Tumor Necrosis Factor Receptor Superfamily Product Portfolio Table 123. Novartis AG Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Tumor Necrosis Factor Receptor Superfamily Distributors List Table 127. Tumor Necrosis Factor Receptor Superfamily Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Receptor Superfamily Product Image Figure 2. Global Tumor Necrosis Factor Receptor Superfamily Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Receptor Superfamily Sales (2021-2032) & (W Units) Figure 5. Global Tumor Necrosis Factor Receptor Superfamily Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. INCAGN-1876 Image Figure 9. GWN-323 Image Figure 10. FPA-154 Image Figure 11. BMS-986156 Image Figure 12. AMG-228 Image Figure 13. Others Image Figure 14. Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Type (2021-2032) Figure 17. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Type (2021-2032) Figure 20. Blood Cancer Image Figure 21. Gastric Cancer Image Figure 22. Melanoma Image Figure 23. Non-Small Cell Lung Cancer Image Figure 24. Others Image Figure 25. Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Application (2021-2032) Figure 28. Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 29. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Application (2021-2032) Figure 31. North America Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 32. North America Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Country (2021-2032) Figure 33. U.S. Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Canada Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Mexico Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Europe Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Country (2021-2032) Figure 38. Germany Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 39. France Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 40. U.K. Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Italy Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Netherlands Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Country (2021-2032) Figure 45. China Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Japan Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South Korea Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 49. India Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Australia Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Country (2021-2032) Figure 53. Brazil Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 54. South Africa Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Turkey Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Argentina Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 58. UAE Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Egypt Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Chile Tumor Necrosis Factor Receptor Superfamily Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Global Tumor Necrosis Factor Receptor Superfamily Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032) & (US$ Million) Figure 64. North America Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032) & (US$ Million) Figure 66. Europe Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Tumor Necrosis Factor Receptor Superfamily Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Tumor Necrosis Factor Receptor Superfamily Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • INCAGN-1876
  • GWN-323
  • FPA-154
  • BMS-986156
  • AMG-228
  • Others
Applications
  • Blood Cancer
  • Gastric Cancer
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Others
Companies covered
  • Ablynx NV
  • Apogenix GmbH
  • Bristol-Myers Squibb Company
  • Five Prime Therapeutics Inc
  • Incyte Corp
  • MedImmune LLC
  • OncoMed Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Amgen Inc
  • Merck & Co Inc
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Receptor Superfamily Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Receptor Superfamily Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tumor Necrosis Factor Receptor Superfamily Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tumor Necrosis Factor Receptor Superfamily Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tumor Necrosis Factor Receptor Superfamily Market Dynamics
  1. 2.1 Tumor Necrosis Factor Receptor Superfamily Industry Trends
  2. 2.2 Tumor Necrosis Factor Receptor Superfamily Industry Drivers
  3. 2.3 Tumor Necrosis Factor Receptor Superfamily Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Receptor Superfamily Industry Restraints
3 Tumor Necrosis Factor Receptor Superfamily Market by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Receptor Superfamily Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Receptor Superfamily Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Receptor Superfamily Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Receptor Superfamily Manufacturers, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Receptor Superfamily Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Receptor Superfamily Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Receptor Superfamily Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Receptor Superfamily Market by Type
  1. 4.1 Tumor Necrosis Factor Receptor Superfamily Type Introduction
  2. 4.1.1 INCAGN-1876
  3. 4.1.2 GWN-323
  4. 4.1.3 FPA-154
  5. 4.1.4 BMS-986156
  6. 4.1.5 AMG-228
  7. 4.1.6 Others
  8. 4.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type
  9. 4.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021-2032)
  11. 4.2.3 Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Type (2021-2032)
  12. 4.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type
  13. 4.3.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2021-2032)
  15. 4.3.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Type (2021-2032)
5 Tumor Necrosis Factor Receptor Superfamily Market by Application
  1. 5.1 Tumor Necrosis Factor Receptor Superfamily Application Introduction
  2. 5.1.1 Blood Cancer
  3. 5.1.2 Gastric Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Non-Small Cell Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application
  8. 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021-2032)
  10. 5.2.3 Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Application (2021-2032)
  11. 5.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application
  12. 5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2021-2032)
  14. 5.3.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Application (2021-2032)
6 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region
  1. 6.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region (2021-2026)
  4. 6.2.2 Global Tumor Necrosis Factor Receptor Superfamily Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region
  1. 7.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region
  2. 7.1.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region (2021-2026)
  4. 7.1.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region (2027-2032)
  5. 7.1.4 Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032)
  8. 7.2.2 North America Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032)
  11. 7.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Ablynx NV
  2. 8.1.1 Ablynx NV Company Information
  3. 8.1.2 Ablynx NV Business Overview
  4. 8.1.3 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  6. 8.1.5 Ablynx NV Recent Developments
  7. 8.2 Apogenix GmbH
  8. 8.2.1 Apogenix GmbH Company Information
  9. 8.2.2 Apogenix GmbH Business Overview
  10. 8.2.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  12. 8.2.5 Apogenix GmbH Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 Five Prime Therapeutics Inc
  20. 8.4.1 Five Prime Therapeutics Inc Company Information
  21. 8.4.2 Five Prime Therapeutics Inc Business Overview
  22. 8.4.3 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  24. 8.4.5 Five Prime Therapeutics Inc Recent Developments
  25. 8.5 Incyte Corp
  26. 8.5.1 Incyte Corp Company Information
  27. 8.5.2 Incyte Corp Business Overview
  28. 8.5.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  30. 8.5.5 Incyte Corp Recent Developments
  31. 8.6 MedImmune LLC
  32. 8.6.1 MedImmune LLC Company Information
  33. 8.6.2 MedImmune LLC Business Overview
  34. 8.6.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  36. 8.6.5 MedImmune LLC Recent Developments
  37. 8.7 OncoMed Pharmaceuticals Inc
  38. 8.7.1 OncoMed Pharmaceuticals Inc Company Information
  39. 8.7.2 OncoMed Pharmaceuticals Inc Business Overview
  40. 8.7.3 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  42. 8.7.5 OncoMed Pharmaceuticals Inc Recent Developments
  43. 8.8 Regeneron Pharmaceuticals Inc
  44. 8.8.1 Regeneron Pharmaceuticals Inc Company Information
  45. 8.8.2 Regeneron Pharmaceuticals Inc Business Overview
  46. 8.8.3 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  48. 8.8.5 Regeneron Pharmaceuticals Inc Recent Developments
  49. 8.9 Amgen Inc
  50. 8.9.1 Amgen Inc Company Information
  51. 8.9.2 Amgen Inc Business Overview
  52. 8.9.3 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  54. 8.9.5 Amgen Inc Recent Developments
  55. 8.10 Merck & Co Inc
  56. 8.10.1 Merck & Co Inc Company Information
  57. 8.10.2 Merck & Co Inc Business Overview
  58. 8.10.3 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  60. 8.10.5 Merck & Co Inc Recent Developments
  61. 8.11 Novartis AG
  62. 8.11.1 Novartis AG Company Information
  63. 8.11.2 Novartis AG Business Overview
  64. 8.11.3 Novartis AG Tumor Necrosis Factor Receptor Superfamily Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis AG Tumor Necrosis Factor Receptor Superfamily Product Portfolio
  66. 8.11.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tumor Necrosis Factor Receptor Superfamily Value Chain Analysis
  2. 9.1.1 Tumor Necrosis Factor Receptor Superfamily Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tumor Necrosis Factor Receptor Superfamily Production Mode & Process
  6. 9.2 Tumor Necrosis Factor Receptor Superfamily Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tumor Necrosis Factor Receptor Superfamily Distributors
  9. 9.2.3 Tumor Necrosis Factor Receptor Superfamily Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst